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Background/Aims. The aim of this study was to compare the eﬀects of ursodeoxycholic acid (UDCA) alone and UDCA plus
domperidone on dissolution of solitary or multiple gallstones. Methods. Fifty-three patients with cholesterol gallstones were
randomized into three treatment groups: group I (n = 22) was given UDCA (15mg/kg/day) alone and group II (n = 18) was
treated with domperidone (30mg/day) in addition to UDCA. The control group (n = 13) was followed without a medical
treatment. Gallbladder volumes and ejection fractions were measured sonographically in all patients before and after treatment.
Results. After 12 months of treatment, stone dissolution was found in 9 (40.9%) of the patients in group I and 7 (38.8%) of the
patients in group II. The diﬀerence was statistically signiﬁcant compared to controls in both treatment groups (P<0.05) but
the two groups did not show a diﬀerence between each other (P>0.05). All the patients that achieved dissolution had multiple
gallstones except for one patient with a solitary stone in group I. Neither monotherapy of UDCA nor the combination with
domperidone aﬀected the ejection fraction of gallbladder. Conclusions. Combination with domperidone did not potentiate the
eﬃcacy of UDCA. It has been observed that both UDCA alone and UDCA plus domperidone treatment did not aﬀect ejection
fraction of gallbladder.
1.Introduction
Gallstones are a major cause of morbidity and mortality
throughout the world. The prevalence of gallstone disease
in western industrialized nations is about 10–15% [1–3].
Although, 2/3 of all gallstones remain asymptomatic (so
called silent gallstone), recurrent episodes of upper abdom-
inal pain related to gallstones are the most common indica-
tion for the treatment of gallstones [2, 4]. Cholecystectomy
is the standard and deﬁnitive treatment for symptomatic
gallbladder stones and can be performed regardless of the
type, number, and size of the stones [1, 5, 6]. However, some,
20%, of patients continue to suﬀer from pain after cholecys-
tectomy [7].
Nonsurgical management of gallstones has made con-
siderable progress within the past 20 years [2, 8]. Recent
studies have raised the possibility that cholesterol-lowering
agents that inhibit hepatic cholesterol synthesis (statins) or
intestinal cholesterol absorption (ezetimibe), or drugs acting
on speciﬁc nuclear receptors involved in cholesterol and
bile acid homeostasis, may oﬀer, alone or in combination,
additional medical therapeutic tools for treating cholesterol
gallstones [3, 5, 6]. Ursodeoxycholic acid is a bile salt that
reduces the secretion of cholesterol into bile and increases
cholesterol solubility. It may also improve gallbladder emp-
tying [2, 4, 9]. Oral litholysis with UDCA induces cholesterol
desaturation of bile and may lead to gallstone dissolution in
patients with small, radiolucent, cholesterol-enriched stones
in a functioning gallbladder with a patent cystic duct [5,
6, 10]. It has been suggested that treatment with bile acids
may inhibit gallstone related-symptoms and complications2 Gastroenterology Research and Practice
even in patients in whom gallstone dissolution is incomplete
[4, 7, 10].
The motility of the gallbladder is another key player in
gallstone pathogenesis because enlarged fasting gallbladder
volume, together with impaired postprandial and interdiges-
tivegallbladderemptying, isfrequentanddistinctivefeatures
in gallstone patients [5]. Impaired gallbladder motility in
patients with gallstone disease can be corrected by prokinetic
drugs [11, 12]. Domperidone, a peripheral dopamine 2-re-
ceptor antagonist, regulates the motility of gallbladder, gas-
tric, and small intestinal smooth muscle. It is rapidly ab-
sorbed after oral administration, and few side eﬀects have
been reported [12–14].
The aim of this study was to investigate the eﬀects of
UDCA-alone and UDCA plus domperidone on stone disso-
lution, fasting gallbladder volume, and gallbladder ejection
fraction in solitary and multiple radiolucent gallbladder
stones.
2. Methods
Seventy-ﬁve patients (64 female, 11 male; mean age: 45.5 ±
11; age range: 25–77) with asymptomatic or mild sympto-
matic cholesterol gallstone were enrolled in this randomized
study.
Evaluation for each subject included a complete history
andphysicalexamination,completebloodcount,serumcho-
lesterol, triglycerides, aminotransferases, total bilirubin and
alkaline phosphatase, serum amylase, abdominal X-rays, and
abdominal ultrasound.
All gallstone patients were candidates for oral bile acid
therapy (radiolucent gallstones, less than 2cm in diame-
ter, good gallbladder emptying, patent cystic duct, mild
symptoms, and no evidence of acute cholecystitis). Fifty-
eight patients had two or more gallbladder stones termed as
multiple stones whereas remaining 17 patients had solitary
gallbladder stones. There was no history of recent pan-
creatitis, cholangitis, and biliary colic in any of the patients.
Patients who had a history of systemic disease, current preg-
nancy or lactation, alcohol, and medication were excluded.
After12hoursovernightfast,fastening,andpostprandial
gallbladder volumes were measured sonographically before
and 60 minutes after ingestion of a standard liquid test
meal (18.4g fat, 16g protein, 240kcal per 150mL) and
postprandialejectionfractionswerecalculatedinallpatients.
Gallbladder volume was measured using a real-time ultra-
sound scanner (Toshiba SSA-270A, Japan, with a 3.75-mHz
curved transducer). Sonographic studies were performed
by the same investigator. Gallbladder dimension in the
longitudinal, transvers, and saggittal planes were obtained.
The smallest volume obtained after feeding at 60th minute
was determined as postprandial (or residual) gallbladder
volume. Gallbladder volume and ejection fraction were de-
termined using the following formulas [15]:
Gallbladder volume (V) =
π
6
×(L ×W ×H) (1)
V =gallbladdervolume,L =saggittallength,W =width,H =
axial height,
Ejection fraction(E) =
(V0 −Vt)
V0
×100 (2)
E = ejection fraction, V0 = fasting gallbladder volume, Vt =
postprandial (residual) gallbladder volume at time 60
minute.
All patients gave written informed consent and the study
was approved by the local research ethics committee. The
patientswererandomizedintothreetreatmentgroups:group
I( n = 30) received UDCA alone (15mg/kg/day, Ursofalk,
Falk Pharma GmbH, Germany); group II (n = 30) received
UDCA plus 30mg/day domperidone (Motilium, Janssen-
Cilag, Turkey). The control group (n = 15) was followed
without a medical treatment.
The physical examination and blood samples were
repeated in each patient in 3-month intervals during the
treatment period. In addition, gallbladder motility and gall-
stone dissolution rates at the third, sixth, ninth and the
twelfth months were evaluated by ultrasonography in all pa-
tients.
Patients were not allowed to take any other drugs affect-
ing biliary lipids or cholesterol biosynthesis. Patients were
excluded from the study if they exhibited any abnormality of
gallbladder, bile duct, or pancreatic function as determined
by X-ray or ultrasonography. The treatments were discontin-
ued at the 6th month if stone dissolution was not achieved.
Results are presented as mean values ± standard devi-
ation (x ± SD). For statistical comparison of the three
groups before and after treatment one-way ANOVA variance
analysis was used. Within group analysis for comparison
before and after treatments was performed with paired-
student’s t-test. Stone dissolution rates were compared with
chi-square test. The diﬀerence was considered statistically
signiﬁcant if the P value was less than 0.05.
3. Results
Six patients in group I, nine patients in group II were
dropped out of the study because of nonattendance or in-
compatibility with the treatments. In addition, 2 patients
in group I were excluded from the study due to severe
biliary colic in one and acute edematous pancreatitis in
the other. Three patients in group II and two patients in
group III underwent urgent laparoscopic cholecystectomy
and therefore excluded. The ﬁnal analysis was performed
with 22 patients (18 female, 4 male) from the UDCA group,
18 patients (16 female, 2 male) from UDCA plus dompe-
ridone group, and 13 patients (11 female, 2 male) from the
control group. There were no statistically signiﬁcant differ-
ences between groups regarding demographic, clinical and
laboratory data on admission. The patient characteristics are
presented in Table 1.
At the end of the treatment period of 12 months, com-
plete stone clearance was achieved in 9 (40.9%) of the pa-
tients in UDCA group and in 7 (38.8%) of the patients in
UDCA plus domperidone. The diﬀerence was statisticallyGastroenterology Research and Practice 3
Table 1: Demographic and clinic characteristics of groups before the treatment∗.
Parameters UDCA
(n = 22)
UDCA and domperidone
(n = 18)
Control
(n = 13)
Mean age 45.4 ±12 42.7 ±13 49.0 ±8
Gender (F/M) 18/41 6 /21 1 /2
BMI (kg/m2)2 9 .0 ±42 7 .1 ±33 0 .3 ±5
Glucose (mg/dL) 90.5 ±11 99.1 ±20 96.2 ±7
Cholesterol (mg/dL) 182.4 ±34 186.1 ±30 177.0 ±26
HDL-cholesterol (mg/dL) 49.7 ±16 53.5 ±17 43.0 ±9
LDL-cholesterol (mg/dL) 105.0 ±35 104.3 ±51 108.4 ±15
Triglyceride (mg/dL) 136.5 ±75 157.4 ±90 145.7 ±81
Solitary stone 6 4 2
Diameters of solitary stones
(mm) 8.1 ±3.18 .2 ±3.38 ±3.6
Multiple stone 16 14 11
FGVav (mL) 26.6 ±9.62 7 .8 ±13.42 5 .4 ±6.2
RGVav (mL) 7.0 ±37 .8 ±56 .3 ±6
EFav (%) 73.6 ±15 71.9 ±19 75.1 ±18
∗R e s u l t sa r ee x p r e s s e da sm e a n± SD.
BMI: body mass index; FGVav: average fasting gallbladder volume; RGVav: average residual gallbladder volume; EFav: average ejection fraction.
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Figure 1: Stone dissolution rates with time in both treatment
groups.
signiﬁcant compared to controls for both treatment groups
(P<0.05) but the two groups did not show a diﬀerence
between each other (P>0.05). Of the 16 cases that achieved
dissolution, all had multiple gallstones except for one in
UDCA group. Solitary gallstones did not disappear in any
subject treated with UDCA plus domperidone combination
(Figure 1 and Table 2). The gallstone dissolution rate at 12
months was not higher for UDCA plus domperidone than
treatment with UDCA-alone. Gallstones were not dissolved
in any subject in control group.
At the end of the treatment period, no signiﬁcant
diﬀerences in terms of fasting and postprandial gallbladder
volumes were observed between the groups. Similarly, gall-
bladder ejection fraction before and after the end of treat-
ment was similar for all three groups (P>0.05) (Table 3).
Laboratory tests including serum alkaline phosphatase,
cholesterol, aspartate, and alanine aminotransferase were
measured monthly, and results of these tests showed no
change during the treatment periods in all groups (Table 3).
Both regimens showed no signiﬁcant diﬀerence in terms
of side eﬀects or drop-out rate. UDCA and domperidone
were generally tolerated quite well. The drugs did not cause
any severe gastrointestinal or other side eﬀects that required
hospitalisation. The only signiﬁcant side eﬀect was a mild-
to-moderate upper-right quadrant pain sometimes necessi-
tating spasmolytics without any laboratory abnormality in 4
cases in UDCA group and 2 cases in the combination group,
all of which had successful stone dissolution. There was a
remarkable decrease in symptoms in patients that achieved
stone dissolution. In patients with partial stone dissolution
UDCA therapy was continued beyond the study period.
4. Discussion
Cholelithiasis is one of the most common and costly di-
gestive diseases. Gallstones are usually asymptomatic and
no treatment is generally required and laparoscopic chole-
cystectomy is ﬁrst-line therapy for symptomatic gallstones
[6, 7]. So far, UDCA has been recommended as ﬁrst-line
pharmacological therapy in a subgroup of symptomatic pa-
tients with small, radiolucent cholesterol gallstones in a
functioning gallbladder with a patent cystic duct, and its
long-term administration has been shown to promote the
dissolution of cholesterol gallstones [3, 5, 6]. Therapy with
bile salts is suitable for only a minority of patients with
symptomatic cholesterol gallstones who refuse surgery or
have an increased surgical risk [2, 10, 16]. UDCA reduces the
synthesis of cholesterol in the liver and its secretion into bile.
UDCA also prolongs the nucleation time of gallbladder bile
by shifting cholesterol from vesicles to micelles [2, 10, 17].4 Gastroenterology Research and Practice
Table 2: Characteristics of the patients of whom stone dissolution was achieved or not∗.
Parameters
UDCA alone UDCA and domperidone
Solitary (n = 6) Multiple (n = 16) Solitary (n = 4) Multiple (n = 14)
SDΦ
(+)n = 1
SD
(−)n = 5
SD
(+)n = 8
SD
(−)n = 8
SD
(+)n = 0
SD
(−)n = 4
SD
(+)n = 7
SD
(−)n = 7
Age (mean) 35 48.2 ±83 5 .7 ± 11 46.9 ±13 — 45.2 ±93 9 .4 ±54 4 .6 ±12
Gender (F/M) 1/—5 /—7 /25 /2— 4 /—6 /15 /2
BMI (kg/m2) 28 31 28.5 29 — 28.5 27 27
SSav (mm) 7 13 — — — 14.8 — —
FGVav (mL) 23.6 25.4 ±72 7 .9 ±82 6 .6 ±8—2 4 .6 ±92 6 .8 ±42 9 .2 ±17
EFav (%) 69.7 72.0 ±12 75.8 ± 16 75.5 ±17 — 74.6 ±10 72.3 ±13 76.4 ±21
∗R e s u l t sa r ee x p r e s s e da sm e a n± SD.
ΦSD: stone dissolution; BMI: body mass index; SSav:a v e r a g es t o n es i z e ;F G V av: average fasting gallbladder volume; EFav: average gallbladder ejection fraction.
Table 3: Characterisitcs of patients in treatment groups in pre- and posttreatment∗.
Parameters
UDCA alone UDCA and domperidone
Pretreatment Posttreatment P Pretreatment Posttreatment P
BMI (kg/m2)2 9 .0 ±42 8 .8 ±6N S2 7 .1 ±32 7 .1 ±5N S
Glucose (mg/dL) 90.5 ±11 96 ±6N S 9 9 .1 ±20 88 ±13 NS
Cholesterol (mg/dL) 182.4 ±34 178 ±36 NS 186.1 ±30 178 ±59 NS
HDL-Cholesterol (mg/dL) 49.7 ±16 51.2 ±9N S 5 3 .5 ±17 56.7 ±10.6N S
LDL-Cholesterol (mg/dL) 105.0 ±35 105 ±42 NS 104.3 ±51 101 ±56 NS
Triglyceride (mg/dL) 136.5 ±75 142 ±52 NS 157.4 ±90 178 ±49 NS
S o l i t a r y s t o n e 6 5N S4 4N S
Multiple stone 16 8 NS 14 7 NS
FGVav (mL) 26.6 ±9.62 7 .0 ±5.2N S 2 7 .8 ±13.42 9 .2 ±6.4N S
RGVav (mL) 7.0 ±36 .5 ±2.6N S 7 .8 ±57 .8 ±3.7N S
EFav (%) 73.6 ±15 75.9 ±16 NS 71.9 ±19 73.2 ±14 NS
∗R e s u l t sa r ee x p r e s s e da sm e a n± SD.
BMI: body mass index; FGVav: average fasting gallbladder volume; RGVav: average residual gallbladder volume; EFav: average ejection fraction.
NS: not signiﬁcant.
The therapeutic success of the medical dissolution of
gallstones depends substantially on the following factors:
(i) patient selection, (ii) dosage of bile acid, and (iii)
therapy duration. The ideal patient to be treated by medical
therapy is mildly symptomatic, non-obese, with functioning
gallbladder and with radiolucent, ﬂoating stones, not larger
than 5mm in diameter [10, 18, 19].
In the current study, we achieved complete gallstone
dissolution rates of 40.9% with UDCA and 38.8% with com-
bination therapy at 12 months. Stone dissolution rate was
higher in patients with multiple stones compared to those
with solitary stones but this diﬀerence was not statistically
signiﬁcant. Combination of UDCA with domperidone did
not improve complete gallstone dissolution rate, gallbladder
fasting volume, and gallbladder ejection fraction. In both
treatment groups, the use of UDCA reduced incidence of
biliary pain. Stone dissolution rates were increased with
the lengthening of treatment periods. Younger patients
demonstratedhigherratesofdissolutioncomparedtoelderly
subjects. The only solitary stone dissolved with the treatment
was 7mm diameter (see Figure 1, Table 2).
Based on a simple correlation with the gallstone dissolu-
tion rate, small size, radiolucency of gallstone, and preserved
gallbladder function have been listed as indication criteria
for UDCA therapy. Size rather than number of stones is the
primary determinant of the dissolution rate [18, 20, 21].
Gallstones smaller than 5mm show a better dissolution rate
than those exceeding 5mm [20]. Stones of less than 5mm
diameter can be dissolved in almost 79% of cases, whereas
the success rates drop to roughly one-third with stones larger
than 10mm in diameter [10, 18]. With stones more than 15–
20mm diameter, the dissolution time is extremely long [10].
Studies using strict inclusion criteria have found dissolution
r a t e so f5 0t o6 0 % .H o w e v e r ,d i s s o l u t i o nr a t e sa sl o wa s
23% have beenreported inlesswell-selectedpopulations [9].
UDCA therapy can be useful in patients with biliary sludge
ormicrolithiasis,especiallyifrecentlydeveloped[18].UDCA
completely dissolved the stones in 37% of all patients [16].
Jazrawi et al. [22] have found complete stone dissolution as
78% with UDCA treatment at the end of 6 months, whereas
Schoenﬁeld and Marks [23] reported a success rate of 50%
at the end of 24 months. On the other hand, Bazzoli et al.Gastroenterology Research and Practice 5
[24] achieved a stone dissolution rate of as low as 13% at the
endof6months.Thewidevariationinthereportedresponse
rates can be attributable to diﬀerences in patient selection,
doses of bile acid, treatment duration, and the diagnostic
techniques used to document complete stone dissolution
[16].
In previous studies diﬀerent results have been reported
about the eﬀects of UDCA alone or in combination with
other drugs. Combination of UDCA with chenodeoxycholic
acid therapy enhances the biliary levels of UDCA [25].
Zuin et al. [26] have obtained gallstone dissolution rate of
83% with UDCA plus chenodeoxycholic acid combination
in 12 months, whereas Petroni et al. [27] obtained a
30% dissolution rate with the same combination over 24
months. Moreover, Tazuma et al. [28] have found 70% stone
dissolution in multiple stones and 25% in solitary stones
after 12 months treatment with UDCA. In the same study,
combination with simvastatin was not proved superior com-
pared to UDCA treatment alone and was not proved supe-
rior for solitary stones. In our study stone dissolution rate
was lower than those reported by Tazuma et al. [28]. As in
previous studies, we failed to show superiority of combina-
tion therapy over UDCA-alone treatment on dissolution of
multiple or solitary stones.
Gallbladder emptying abnormalities are common in
patients with gallstones, and it has been hypothesized that
they contribute to the increased incidence of gallbladder
stones [4]. In the treatment of gastrointestinal motility dis-
orders 3 prokinetic agents (metoclopramide, domperidone,
andcisapride)havemainlybeenused.Theyarediﬀerentiated
from their pharmacological mode of action, their clinical
eﬃcacy, and tolerability. Domperidone is a pure dopam-
ine receptor antagonist. It antagonizes noradrenaline- and
dopamine-induced relaxations of smooth muscles [29]. We
wondered whether the therapeutic eﬀects of domperidone
and UDCA in gallstone disease might be mediated by
changes in gallbladder contractility. In our study, we found
that neither the UDCA nor domperidone altered fasting
gallbladder volume and ejection fraction in patients with
gallstone at the end of 12 months. Our ﬁndings suggest
that the dissolution of gallstones during oral bile acid ad-
ministration is not paralleled by an improvement in gall-
bladder function. In the literature, diﬀerent results have
been reported about the eﬀects of prokinetics drugs on gall-
bladder motility. Tankurt et al. [12] and Nakayama et al.
[30] demonstrated that domperidone increases gallbladder
contractility in healthy subjects in contrast to Mangiameli
et al. [13] who showed that domperidone has no eﬀect on
contractility.Instudiesperformedwithcisapride,Kapicioglu
et al. [31] demonstrated that this drug did not change the
fasting mean gallbladder volume as compared to the baseline
in the healthy subjects. However, this study showed that
the administration of cisapride causes gallbladder volume
reduction in diabetic patients. Diﬀerently, G¨ ursoy et al.
[32] showed that cisapride did not change the contractil-
ity of gallbladder in diabetic patients. Recently proposed
some molecular mechanisms bring up alternative treatments
for bile stones. For example, the human apical sodium-
dependent bile acid transporter (hASBT) plays a critical role
in the enterohepatic circulation of bile acids and cholesterol
homeostasis whose expression is regulated by FXR [33, 34].
Therefore, the use of FXR agonists could have potential
therapeutic applications in hypercholesterolemia and in
cholestasis, but not in cholesterol gallstone therapy.
We conclude that UDCA treatment should be preferred
for patients with small multiple gallstones and that adminis-
tration of combined UDCA and domperidone is not likely to
provideaneﬀectivecombination.Gallbladderfastingvolume
and ejection fraction did not change at the end of gallstone
dissolution treatment in radiolucent gallstone patients. We
alsodemonstratethatUDCAanddomperidonecombination
have no eﬀect on gallbladder contractility in patients with
gallstone.
In conclusion, we found higher dissolution rates in pa-
tients with multiple stones compared to these with solitary
stones as in previous studies. Younger patient age and longer
treatment periods increased the chance of successful treat-
ment. Long-term medical treatment with bile salts may help
to reduce gallstone-related complications and need for sur-
gery especially in multiple gallstones in which both the risk
of complication and the beneﬁt of therapy are greatest.
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